VANTAGE BIOSCIENCES
Vantage Biosciences is a developer of an oral therapy designed for diabetic eye diseases.
VANTAGE BIOSCIENCES
Social Links:
Industry:
Biotechnology Health Care Product Research Therapeutics
Founded:
2023-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.vantage-biosciences.com
Total Employee:
1+
Status:
Active
Technology used in webpage:
Euro U.S. Server Location
Similar Organizations
Carrick Therapeutics
Carrick Therapeutics is a developer of cancer therapeutics intended to transform the way cancer is treated.
CiMaas
CiMaas develops immunotherapy for cancer by optimally engaging the immune system.
Empyrean Therapeutics
Empyrean Therapeutics develops next generation cell therapies to enable global and affordable cures for diseases.
Landos Biopharma
Landos Biopharma is a developer of an oral first-in-class therapeutics designed to target autoimmune diseases.
Phico Therapeutics
Phico Therapeutics is a developer of novel platform technology designed to overcome antibacterial resistance.
PrEP Biopharm
PrEP Biopharm is a developer of respiratory infectious disease products.
scibac
SciBac is a developer of biotherapeutics intended to treat antibiotic diseases.
Tenaya Therapeutics
Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease.
Investors List
ALSA Ventures
ALSA Ventures investment in Seed Round - Vantage Biosciences
Official Site Inspections
http://www.vantage-biosciences.com
- Host name: 198.202.211.1
- IP address: 198.202.211.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Vantage Biosciences"
Vantage Biosciences
Vantage Biosciences is a UK based clinical stage biotechnology company, with a potential for developing the first oral treatment for diabetic retinopathy. The Vantage Biosciences team …See details»
Vantage Biosciences - Crunchbase Company Profile
Organization. Vantage Biosciences . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. …See details»
Team - Vantage Biosciences
Charmaine brings over 30 years of diverse experience within Research and Development and joined Vantage Biosciences in August 2024 from Gyroscope Therapeutics, a Novartis company. She has held key senior roles across the …See details»
Vantage Biosciences 2025 Company Profile: Valuation, …
Vantage Biosciences General Information Description. Developer of an oral therapy designed for diabetic eye diseases. The company is developing an …See details»
VANTAGE BIOSCIENCES LLC Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for VANTAGE BIOSCIENCES LLC of Scottsdale, AZ. Get the latest business insights from Dun & Bradstreet.See details»
VANTAGE BIOSCIENCES LTD - Companies House
More for VANTAGE BIOSCIENCES LTD (14721262) Registered office address 78 Pall Mall, London, England, SW1Y 5ES . Company status Active Company type Private limited …See details»
Vantage Biosciences - LinkedIn
Vantage Biosciences is a UK-based clinical stage biotechnology company targeting the root cause of vision loss resulting from diabetes – the neuroinflammatory insult that precedes ...See details»
Vantage Biosciences - Funding, Financials, Valuation & Investors
Jul 19, 2023 Vantage Biosciences is a developer of an oral therapy designed for diabetic eye diseases. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. …See details»
Vantage Biosciences Ltd. - Drug pipelines, Patents, Clinical trials ...
Explore Vantage Biosciences Ltd. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 1 news, Disease Domain:Endocrinology and Metabolic Disease, Technology …See details»
Vantage Biosciences - VentureRadar
Vantage Biosciences is targeting the root cause of vision loss resulting from diabetes– the neuroinflammatory insult that precedes microangiopathy and leads to degeneration of the …See details»
Vantage Biosciences - Products, Competitors, Financials, …
Vantage Biosciences chairman and co-founder Alek Safarian said: “We are pleased to initiate patient dosing in this important Phase II study, which evaluates VX-01 as a potential early …See details»
Science and Pipeline - vantage-biosciences.com
Vantage Biosciences believes that amine oxidase copper-containing 3 (AOC-3; also known as vascular adhesion protein 1) is a central player orchestrating this pathological cascade, …See details»
Vantage Biosciences Doses First Patient in Phase 2 Clinical
2 days ago Vantage Biosciences is a clinical stage biotechnology company dedicated to developing innovative therapies for diabetic eye diseases. Founded by ALSA Ventures, the …See details»
Vantage Biosciences LLC - Drug pipelines, Patents, Clinical trials ...
100 Translational Medicine associated with Vantage Biosciences LLC. Login to view more data. Corporation Tree. Boost your research with our corporation tree data. login. or. view full …See details»
Home - Vantage Biotrials
Services and Solutions Project Management Vantage BioTrials’ Project Managers are the glue that bind relationships with Sponsors. Our PMs break down barriers to allow other team …See details»
ALSA Ventures launches Vantage Biosciences to treat Diabetic Eye ...
At Vantage Biosciences, we are targeting the root cause of vision loss resulting from diabetes – the neuroinflammatory insult that precedes microangiopathy and leads to degeneration of the ...See details»
Vantage Biosciences
London, UK – November 1, 2023 – Vantage Biosciences Ltd, a clinical-stage biotechnology company developing an oral small-molecule therapy for treatment of diabetic retinopathy, …See details»
VX 01 - AdisInsight - Springer
VX 01, an orally available, small molecule AOC-3 inhibitor is being developed by Vantage Biosciences for the treatment of diabetic eye disorders including VX 01 Next Previous Table of …See details»
Our Science
Vantage Biosciences is dedicated to unlocking the potential of cutting-edge science to address inflammatory conditions driven by leukocyte trafficking and oxidative stress. AOC-3 has a dual …See details»
Latest news - Vantage Biosciences
Keep up to date with all the latest Vantage Biosciences news. November 23, 2023. Vantage Biosciences to Present at Ophthalmology Innovation Summit XIII . July 19, 2023. ALSA …See details»